These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 36209317)

  • 21. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.
    Scorpio A; Lindholm-Levy P; Heifets L; Gilman R; Siddiqi S; Cynamon M; Zhang Y
    Antimicrob Agents Chemother; 1997 Mar; 41(3):540-3. PubMed ID: 9055989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of Novel Efflux Proteins Rv0191, Rv3756c, Rv3008, and Rv1667c Involved in Pyrazinamide Resistance in Mycobacterium tuberculosis.
    Zhang Y; Zhang J; Cui P; Zhang Y; Zhang W
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study.
    Miotto P; Cabibbe AM; Feuerriegel S; Casali N; Drobniewski F; Rodionova Y; Bakonyte D; Stakenas P; Pimkina E; Augustynowicz-Kopeć E; Degano M; Ambrosi A; Hoffner S; Mansjö M; Werngren J; Rüsch-Gerdes S; Niemann S; Cirillo DM
    mBio; 2014 Oct; 5(5):e01819-14. PubMed ID: 25336456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atypical Genetic Basis of Pyrazinamide Resistance in Monoresistant Mycobacterium tuberculosis.
    Modlin SJ; Marbach T; Werngren J; Mansjö M; Hoffner SE; Valafar F
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33722890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug resistance mechanism of PncA in Mycobacterium tuberculosis.
    Rajendran V; Sethumadhavan R
    J Biomol Struct Dyn; 2014; 32(2):209-21. PubMed ID: 23383724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Turkey.
    Yüksel P; Tansel O
    New Microbiol; 2009 Apr; 32(2):153-8. PubMed ID: 19579692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pyrazinamide Susceptibility and
    Rahman A; Ferdous SS; Ahmed S; Rahman SMM; Uddin MKM; Pholwat S; Gratz J; Houpt E; Banu S
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overcoming the Challenges of Pyrazinamide Susceptibility Testing in Clinical Mycobacterium tuberculosis Isolates.
    Mok S; Roycroft E; Flanagan PR; Montgomery L; Borroni E; Rogers TR; Fitzgibbon MM
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0261720. PubMed ID: 33972244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant mycobacterium tuberculosis strains.
    Sekiguchi J; Nakamura T; Miyoshi-Akiyama T; Kirikae F; Kobayashi I; Augustynowicz-Kopec E; Zwolska Z; Morita K; Suetake T; Yoshida H; Kato S; Mori T; Kirikae T
    J Clin Microbiol; 2007 Sep; 45(9):2802-7. PubMed ID: 17596354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic surveillance and outcomes of pyrazinamide and fluoroquinolones-resistant tuberculosis in Taiwan.
    Huang HT; Lin WH; Chan TH; Jou R
    J Microbiol Immunol Infect; 2023 Dec; 56(6):1236-1244. PubMed ID: 37690869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China.
    Che Y; Bo D; Lin X; Chen T; He T; Lin Y
    BMC Infect Dis; 2021 Jun; 21(1):605. PubMed ID: 34171989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. pncA mutations in clinical Mycobacterium tuberculosis isolates from Korea.
    Park SK; Lee JY; Chang CL; Lee MK; Son HC; Kim CM; Jang HJ; Park HK; Jeong SH
    BMC Infect Dis; 2001; 1():4. PubMed ID: 11429043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overcoming the pitfalls of automatic interpretation of whole genome sequencing data by online tools for the prediction of pyrazinamide resistance in Mycobacterium tuberculosis.
    Iwamoto T; Murase Y; Yoshida S; Aono A; Kuroda M; Sekizuka T; Yamashita A; Kato K; Takii T; Arikawa K; Kato S; Mitarai S
    PLoS One; 2019; 14(2):e0212798. PubMed ID: 30817803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan.
    Huang TS; Lee SS; Tu HZ; Huang WK; Chen YS; Huang CK; Wann SR; Lin HH; Liu YC
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3672-3. PubMed ID: 14576145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging insight of whole genome sequencing coupled with protein structure prediction into the pyrazinamide-resistance signature of Mycobacterium tuberculosis.
    Huang CK; Yu MC; Hung CS; Lin JC
    Int J Antimicrob Agents; 2024 Apr; 63(4):107053. PubMed ID: 38081550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis.
    Zhang S; Chen J; Shi W; Liu W; Zhang W; Zhang Y
    Emerg Microbes Infect; 2013 Jun; 2(6):e34. PubMed ID: 26038471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Chain Fatty Acyl Coenzyme A Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis.
    Rosen BC; Dillon NA; Peterson ND; Minato Y; Baughn AD
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance.
    Zimic M; Fuentes P; Gilman RH; Gutiérrez AH; Kirwan D; Sheen P
    Tuberculosis (Edinb); 2012 Jan; 92(1):84-91. PubMed ID: 22004792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural dynamics behind variants in pyrazinamidase and pyrazinamide resistance.
    Khan MT; Malik SI
    J Biomol Struct Dyn; 2020 Jul; 38(10):3003-3017. PubMed ID: 31357912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring the Pyrazinamide Drug Resistance Mechanism of Clinical Mutants T370P and W403G in Ribosomal Protein S1 of Mycobacterium tuberculosis.
    Rehman AU; Khan MT; Liu H; Wadood A; Malik SI; Chen HF
    J Chem Inf Model; 2019 Apr; 59(4):1584-1597. PubMed ID: 30810312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.